In this study, we showed that anti-PAR1 antibody might be useful for both diagnosis of the risk of breast cancer recurrence after surgery in HER2-negative and PAR1-positive patients and therapy for PAR1-positive patients as an anticancer drug acting against PAR1. The gene discussed is ERBB2; the disease is breast carcinoma.